COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

Nature Reviews Drug Discovery

Volumn 2, Issue 11, 2003, Pages 879-890

  FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; ANAKENA; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICLOFENAC POTASSIUM; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTAGLANDIN INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ATHEROSCLEROSIS; CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; LIVER TOXICITY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; STOMACH ULCER; THROMBOSIS;

EID: 0242690224     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1225     Document Type: Review

References (147)

1. Smith, W. L., Dewitt, D. L. & Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182 (2000).
2. Malkowski, M. G., Ginell, S. F., Smith, W. L. & Garavito, R. M. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 289, 1933-1937 (2000).
3. Reid, G. et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl Acad. Sci. USA 100, 9244-9249 (2003).
4. Schuster, V. L. Prostaglandin transport. Prostaglandins Other Lipid Mediat. 68-69, 633-647 (2002).
5. 2α receptor-dependent regulation of prostaglandin transport. Mol. Pharmacol. 6, 1506-1513 (2001).
6. 2 metabolite binds peroxisome proliferator-activated receptor-γ and promotes adipocyte differentiation. Cell 83, 813-819 (1995).
7. 2 and the ligation of PPAR-γ. J. Clin. Invest. 112, 945-955 (2003).
8. Xie, W., Chipman, J. G., Robertson, D. L., Erikson, R. L. & Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA 88, 1692-1696 (1991).
9. Kujubu, D. A. & Herschman, H. R. Dexamethasone inhibits mitogen induction of the T1s10 prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem. 267, 7991-7994 (1992).
10. O'Banion, M. K., Winn, V. D. & Young, D. A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl Acad. Sci. USA 89, 4888-4892 (1992).
11. Grosser, T., Yusuff, S., Cheskis, E., Pack, M. A. & FitzGerald, G. A. Developmental expression of functional cyclooxygenases in zebrafish. Proc. Natl Acad. Sci. USA 99, 8418-8423 (2002).
12. McAdam, B. F. et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Invest. 105, 1473-1482 (2000).
13. Komers, R. & Epstein, M. Cyclooxygenase-2 expression and function in renal pathophysiology. J. Hypertens. 6, S11-S15 (2002).
14. Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A. & Worley, P. F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11, 371-386 (1993).
15. Luong, C. et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct. Biol. 3, 927-933 (1996).
16. FitzGerald, G. A. & Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345, 433-442 (2001).
17. Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343, 1520-1528 (2000).
18. Juni, P., Rutjes, A. W. & Dieppe, P. A. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs. BMJ 324, 1287-1288 (2002).
19. Chavez, M. L. & DeKorte C. J. Valdecoxib: a review. Clin. Ther. 25, 817-851 (2003).
20. Patrignani, P., Capone, M. L. & Tacconelli, S. Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. Expert Opin. Pharmacother. 4, 265-284 (2003).
21. Dougados, M. et al. Anti-inflammatory treatment effect of NSAIDs in ankylosing spondylitis (AS) patients with and without concomitant peripheral arthritis. Ann. Rheum. Dis. 62 (Suppl. 1), 21 (2003).
22. Dalkh, D. I. et al. Baseline pain severity and response to treatment with etoricoxib and indomethacin for acute gouty arthritis: a subgroup analysis. Ann. Rheum. Dis. 62 (Suppl. 1), 284 (2003).
23. Benevolenskaya, L., Tuzun, S., Hagin, E., Moore, A. & Gimona, A. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4 weeks of treatment: results from a randomized, placebo-controlled trial. Ann. Rheum. Dis. 62 (Suppl. 1), 270 (2003).
24. Weaver, M. L., Flood, D. J., Kimble, E. F. & Fujimoto, R. A. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. Ann. Rheum. Dis. 62 (Suppl. 1), 378 (2003).
25. Cannon, G. W., Krupa, D. A., McCormick, C. L., Mehta, A. & Reicin, A. S. Rofecoxib has a lower incidence of increased liver function tests (LFTs) and LFT-related adverse events in comparison to diclofenac. Ann. Rheum. Dis. 62 (Suppl. 1), 485 (2003).
26. Amat, M. et al. Preclinical profile of LAS34475, a third generation selective COX-2 inhibitor. Ann. Rheum. Dis. 62 (Suppl. 1), 259 (2003).
27. FitzGerald, G. A. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 361, 542-544 (2003).
28. Mavros, P. et al. Association between health-related quality of life changes and clinical efficacy endpoints in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62 (Suppl. 1), 538 (2003).
29. Moore, A. et al. Cost-effectiveness of etoricoxib compared to traditional NSAIDs in the UK. Ann. Rheum. Dis. 62 (Suppl. 1), 538 (2003).
30. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
31. Patrignani, P., Filabozzi, P. & Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69, 1366-1372 (1982).
32. 2 as an amplifying signal for other agonists. Am. J. Cardiol. 68, 11B-15B (1991).
33. Moncada, S. & Vane, J. R. Prostacyclin and the vascular endothelium. Bull. Eur. Physiopathol. Respir. 17, 687-701 (1981).
34. Gimbrone, M. A. Jr. Topper, J. N., Nagel, T., Anderson, K. R. & Garcia-Cardena, G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. NY Acad. Sci. 902, 230-239 (2000).
35. McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Lawson, J. A. & FitzGerald, G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Natl Acad. Sci. USA 96, 272-277 (1999).
36. Catella-Lawson, F. et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J. Pharm. Exp. Ther. 289, 735-741 (1999).
37. FitzGerald, G. A., Pedersen, A. K. & Patrono, C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67, 1174-1177 (1983).
38. Vane, J. R. Biomedicine. Back to an aspirin a day? Science 296, 474-475 (2002).
39. FitzGerald, G. A., Smith, B., Pedersen, A. K. & Brash, A. R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N. Engl. J. Med. 310, 1065-1068 (1984).
40. Fitzgerald, D. J., Roy, L., Catella, F. & FitzGerald, G. A. Platelet activation in unstable coronary disease. N. Engl. J. Med. 315, 983-989 (1986).
41. 2 metabolites during leg exercise in humans. Am. J. Physiol. 255, H15-H18 (1988).
42. Roy, L., Knapp, H. R., Robertson, R. M. & FitzGerald, G. A. Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. Circulation 71, 434-440 (1985).
43. Singer, I. I., Kawka, D. W., Cunningham, P., Ouellet, M. & Riendeau, D. COX-1 is the major isoform of cyclooxygenase co-localized with prostacyclin synthase in normal dog aortic endothelium. Inflammation Res. 52 (Supplement 2), S79-S209 (2003).
44. Fitzgerald, D. J., Fragetta, J. & FitzGerald, G. A. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J. Clin. Invest. 82, 1708-1713 (1988).
45. 2. Science 296, 539-541 (2002).
46. Braden, G. A., Knapp, H. R. & FitzGerald, G. A. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation 84, 679-685 (1991).
47. 2 inhibits cAMP production and promotes platelet aggregation. J. Clin. Invest. 107, 603-610 (2001).
48. 2 receptors in control of murine renal hemodynamics. Am. J. Physiol. Heart Circ. Physiol. 280, H327-H333 (2001).
49. 2 receptor. Nature Med. 5, 217-220 (1999).
50. 2 interactions in spontaneously hypertensive rats. Hypertension 22, 688-698 (1993).
51. Murata, T. et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388, 678-682 (1997).
52. Whelton, A., Kent, J. D. & Recker, D. P. No difference in thrombotic events in rheumatoid arthritis patients: valdecoxib vs naproxen and placebo. Ann. Rheum. Dis. 62 (Suppl. 1), 277 (2003).
53. Konstam, M. A. et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104, 2280-2288 (2001).
54. Reicin, A. et al. Cardiovascular safety profile of rofecoxib in elderly patients with Alzheimer's disease or cognitive impairment: an updated pooled analysis. Ann. Rheum. Dis. 62 (Suppl. 1), 407 (2003).
55. White, W. B., Verburg, K. M. & Whelton, A. The cyclooxygenase-2 specific inhibitor, valdecoxib, is not associated with an increased risk of cardiovascular thrombotic events in arthritis patients. Ann. Rheum. Dis. 62 (Suppl. 1), 160 (2003)
56. Layton, D., Heeley, E., Hughes, K. & Shakir, S. A. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford) 2003 July 16 (DOI 10.1093/rheumatology/keg401).
57. Wallberg-Jonsson, S., Cederfelt, M. & Rantapaa Dahlquist, S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year follow-up study. J. Rheumatol. 27, 71-75 (2000).
58. DeMaria, A. N. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J. Cardiol. 89, 33D-38D (2002).
59. Silverstein, F. E. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal and inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. J. Am. Med. Assoc. 284, 1247-1255 (2000).
60. Strand, V. & Hochberg, M. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibtors. Arthritis Rheum. 47, 349-355 (2002).
61. Curtis, S. The efficacy and safety of etoricoxib. Proc. Intl Workshop COX-2, Rome, 31 December 2002.
62. McCormack, P. L., Cheer, S. M., Keam, S. J. & Goa, K. L. Parecoxib: a review of its use in the short-term treatment of postoperative pain. Drugs 63 (in the press).
63. Ott, E. et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 125, 1481-1492 (2003).
64. Reilly, I. A., Doran, J. B., Smith, B. & FitzGerald, G. A. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 73, 1300-1309 (1986).
65. 2 levels during cardiopulmonary bypass. Circulation 61, 808-814 (1980).
66. Reilly, I. A. & FitzGerald, G. A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69, 180-186 (1987).
67. Garcia Rodriguez, L. A., Varas, C. & Patrono, C. Differential effects of aspirin and nonaspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 11, 382-387 (2000).
68. van Hecken, A. et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. 40, 1109-1120 (2000).
69. Knijff-Dutmer, E. A., Martens, A. & vd Laar, M. A. Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis. Ann. Rheum. Dis. 58, 257-259 (1999).
70. Krishnan, E., Lingala, V. & Singh, G. Naproxen does not reduce the risk of cardiovascular thromboembolic events in patients with rheumatoid arthritis not taking concomitant aspirin: results from a prospective observational cohort study of 6,149 patients with 33,257 person years of follow-up. Ann. Rheum. Dis. 61 (Suppl. 1), 55 (2002).
71. Ray, W. A., Stein, C. M., Hall, K., Kaugherty, J. R. & Griffin, M. R. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359, 118-123 (2002).
72. Ray, W. A. et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360, 1071-1073 (2002).
73. Schlienger, R. G., Jick, H. & Meier, C. R. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br. J. Clin. Pharmacol. 54, 327-332 (2002).
74. Mamdani, M. et al. Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch. Intern. Med. 163, 481-486 (2003).
75. Solomon, D. H., Glynn, R. J., Levin, R. & Avora, J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med. 162, 1099-1104 (2002).
76. Watson, D. J., Rhodes, T., Cai, B. & Guess, H. A. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. 162, 1105-1110 (2002).
77. Crofford, L. J. et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase-2 inhibitors. A report of four cases. Arthritis Rheum. 43, 1891-1896 (2000).
78. Patrono, C. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119, 39S-63S (2001).
79. Catella-Lawson, F. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345, 1809-1817 (2001).
80. Kurth, T. et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 108, 1191-1195 (2003).
81. MacDonald, T. M. & Wei, L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361, 573-574 (2003).
82. Curtis, J. P. et al. Aspirin, ibuprofen, and mortality among elderly survivors of myocardial infarction: a retrospective cohort study. BMJ (in the press).
83. Patrignani, P. et al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J. Physiol. Pharmacol. 50, 661-667 (1999).
84. Breyer, M. D. & Harris, R. C. Cyclooxygenase-2 and the kidney. Curr. Opin. Nephrol. Hypertens. 10, 89-98 (2001).
85. Curhan, G. C., Willett, W. C., Rosner, B. & Stampfer, M. J. Frequency of analgesic use and risk of hypertension in younger women. Arch. Intern. Med. 162, 2204-2208 (2002).
86. Armstrong, E. P. & Maloney D. C. The impact of nonsteroidal and anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin. Ther. 25, 1-18 (2003).
87. FitzGerald, G. A. The choreography of cyclooxygenases in the kidney. J. Clin. Invest. 110, 61-69 (2002).
88. Athirakul, K., Kim, H. S., Audoly, L. P., Smithies, O. & Coffman, T. M. Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibitions. Kidney Int. 60, 2324-2329 (2001).
89. Qi, Z. et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110, 61-69 (2002).
90. Gurley, S. B., Le, T. H. & Coffman, T. M. Gene-targeting studies of the renin-angiotensin system: mechanisms of hypertension and cardiovascular disease. Cold Spring Harb. Symp. Quant. Biol. 67, 451-457 (2002).
91. Nielsen, C. B., Bech, J. N. & Pedersen, E. B. Effects of prostacyclin on renal haemodynamics, renal tubular function and vasoactive hormones in healthy humans. A placebo-controlled dose-response study. Br. J. Clin. Pharmacol. 44, 471-476 (1997).
92. - and NO. Am J. Physiol. Renal Physiol. 279, F302-F308 (2000).
93. Yang, X. et al. Hypoxic induction of COX-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 27, 688-696 (2002).
94. Hoshikawa, Y. et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am. J. Respir. Crit. Care Med. 164, 314-318 (2001).
95. Kao, P. N. & Faul, J. L. Emerging therapies for pulmonary hypertension: striving for efficacy and safety. J. Am. Coll. Cardiol. 41, 2126-2129 (2003).
96. Barber, S. R., Champion, H. C., Bivalacqua, T. J., Hyman, A. L. & Kadowitz, P. J. Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation 108, 896-901 (2003).
97. Schonbeck, U., Sukhova, G. K., Graber, P, Coulter, S. & Libby, P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155, 1281-1291 (1999).
98. Belton, O., Byrne, D., Kearney, D., Leahy, A. & Fitzgerald, D. J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102, 840-845 (2000).
99. Widlansky, M. E. et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42, 310-315 (2003).
100. Chenevard, R. et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107, 405-409 (2003).
101. Monobe, H., Yamanari, H., Nakamura, K. & Ohe, T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin. Cardiol. 24, 705-709 (2001).
102. Bulut, D. et al. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J. Hypertens. 21, 1663-1667 (2003).
103. Cipollone, F. et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107, 1479-1485 (2003).
104. 2-dependent plaque instability. Circulation 104, 921-927 (2001).
105. Rott, D. et al. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J. Am. Coll. Cardiol. 41, 1812-1819 (2003).
106. Pratico, D., Tillmann, C., Zhang, Z. B., Li, H. & FitzGerald, G. A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl Acad. Sci. USA 98, 3359-3363 (2001).
107. Olesen, M. et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand. Cardiovasc. J. 36, 362-367 (2002).
108. Egan, K. M., Pratico, D., Powell-Braxton, L. & FitzGerald, G. A. Cyclooxygenase dependent and independent ligation of the thromboxane receptor accelerates atherogenesis. Circulation 104, 64 (2001).
109. Burleigh, M. E. et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105, 1816-1823 (2002).
110. 2 suppresses chemokine production in human macrophages through the EP4 receptor. J. Biol. Chem. 277, 44147-44154 (2002).
111. Cayatte, A. J. et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 1724-1728 (2000).
112. Egan, K. M., Austin, S. C., Smyth, E. M. & FitzGerald, G. A. Accelerated atherogenesis in prostacyclin receptor deficient mice. Circulation 102, 850 (2000).
113. Adderley, S. R. & Fitzgerald, D. J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinase-mediated induction of cyclooxygenase-2. J. Biol. Chem. 274, 5038-5046 (1999).
114. Dowd, N. P., Scully, M., Adderley, S. R., Cunningham, A. J. & Fitzgerald, D. J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest. 108, 585-590 (2001).
115. Xuan, Y. T. et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J. Mol. Cell. Cardiol. 35, 525-537 (2003).
116. Shinmura, K. et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl Acad. Sci. USA 97, 10197-10202 (2000).
117. 2 in cardiac ischemia-reperfusion injury: a study using mice-lacking their respective receptors. Circulation 104, 2210-2215 (2001).
118. Wong, S. C., Fukuchi, M., Melnyk, P., Rodger, I. & Giaid, A. Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation 98, 100-103 (1998).
119. Zhang, Z. et al. COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ. Res. 92, 1153-1161 (2003).
120. Sheehan, K. M. et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282, 1254-1257 (1999).
121. Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000).
122. Oshima, M. et al. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803-809 (1996).
123. Chulada, P. C. et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60, 4705-4708 (2000).
124. Thun, M. J., Henley, S. J. & Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic pharmacologic, and clinical issues. J. Natl Cancer Inst. 94, 252-266 (2002).
125. Aisen, P. S. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289, 2819-2826 (2003).
126. Teismann, P. et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 100, 5473-5478 (2003).
127. McCown, T. J., Knapp, D. J. & Crews, F. T. Inferior collicular seizure generalization produces site-selective cortical induction of cylcooxygenase 2 (COX-2). Brain Res. 767, 370-374 (1997).
128. Xiang, Z. et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 10, 271-278 (2002)
129. Rich, J. B. et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51-55 (1995).
130. Memo, M., Blandini, F., Nappi, G. & Spano, P. Neuroprotection: promise and pitfalls in anti-inflammatory treatment of Alzheimer's disease. Funct. Neurol. 17, 175-176 (2002)
131. Weggen, S. et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β 42 production by direct modulation of γ-secretase activity. J. Biol. Chem. 278, 31831-31837 (2003).
132. Erikson, J. L. et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower amyloid β 42 in vivo. J. Clin. Invest. 112, 440-449 (2003).
133. Agdeppa, E. D. et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[18)F] fluoroethyl) (methyl)amino]-2-naphthyl ethylidene)malononitrile. Neuroscience 117, 723-730 (2003).
134. Chandrasekharan, N. V. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl Acad. Sci. USA 99, 13926-13931 (2002).
135. Trebino, C. E. et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl Acad. Sci. USA 100, 9044-9049 (2003).
136. Kojima, F. et al. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J. Rheumatol. 29, 1836-1842 (2002).
137. 2 production in the rat adjuvant-induced arthritis model. J. Immunol. 170, 4738-4744 (2003).
138. 2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J. Biol. Chem. 2003 June 30 (DOI 10.1074/jbc.M305108200).
139. 2 biosynthesis. J. Biol. Chem. 275, 32775-32782 (2000).
140. Gerritsen, M. E. & Cheli, C. D. Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells. J. Clin. Invest. 72, 1658-1671 (1983).
141. Sennlaub, F. et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 107, 198-204 (2003).
142. Narumiya, S. & FitzGerald, G. A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108, 25-30 (2001).
143. Walter, M. F., Jacob, R. F. & Preston Mason, R. P. Sulfone COX-2 inhibitors increase susceptability of low density lipoprotein to oxidative modification. Circulation (in the press).
144. Frishman, W. H. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am. J. Cardiol. 89, 18D-25D (2002).
145. 2 synthase. Nature Struct. Biol. 2, 637-643 (1995).
146. Kurumbail, R. G. et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384, 644-648 (1996).
147. Trummlitz, G. & van Ryn, J. Designing selective COX-2 inhibitors: molecular modeling approaches. Curr. Opin. Drug Discov. Dev. 5, 550-561 (2002).